ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. [electronic resource]
Producer: 20150220Description: 3738-47 p. digitalISSN:- 1528-0020
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Blotting, Western
- Bridged Bicyclo Compounds, Heterocyclic -- administration & dosage
- Cell Line, Tumor
- Cell Survival -- drug effects
- Cells, Cultured
- Child
- Drug Synergism
- Gene Expression Profiling
- Gene Expression Regulation, Leukemic -- drug effects
- HEK293 Cells
- Humans
- Inhibitory Concentration 50
- Jurkat Cells
- Mice, Inbred NOD
- Mice, SCID
- Oligonucleotide Array Sequence Analysis
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Reverse Transcriptase Polymerase Chain Reaction
- Sulfonamides -- administration & dosage
- Survival Analysis
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.